What the Clinician Needs to Know About Laboratory Analyses of Circulating Tumor DNA

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2025-01-25 DOI:10.1016/j.clcc.2025.01.003

Cecilie Mondrup Jacobsen , Luisa Matos do Canto , Søren Kahns , Torben Frøstrup Hansen , Rikke Fredslund Andersen

{"title":"What the Clinician Needs to Know About Laboratory Analyses of Circulating Tumor DNA","authors":"Cecilie Mondrup Jacobsen , Luisa Matos do Canto , Søren Kahns , Torben Frøstrup Hansen , Rikke Fredslund Andersen","doi":"10.1016/j.clcc.2025.01.003","DOIUrl":null,"url":null,"abstract":"<div><div>Liquid biopsies offer the possibility to evaluate cancer patients using noninvasive approaches. Circulating cell-free DNA (ccfDNA) is 1 of the most used and promising sources. Detecting tumor DNA among ccfDNA (ctDNA) can be used for early cancer detection, treatment response assessment, prognosis, and predictive evaluations. Providing analyses that can increase the quality of patient treatment is very much a joint effort between laboratory scientists and clinicians. With its use approaching clinical practice, it is important for clinicians to be familiar with the basic concepts and analyses behind ctDNA results in a similar way as laboratory scientists should have knowledge of the clinical needs to provide relevant analyses. In this Perspective, we describe the whole process of ctDNA analyses, from the preanalytical standards to reporting/analyzing results, and highlight some important factors that need to be addressed in the process of implementing them to clinical practice.</div></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"24 2","pages":"Pages 109-119"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical colorectal cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002825000039","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Liquid biopsies offer the possibility to evaluate cancer patients using noninvasive approaches. Circulating cell-free DNA (ccfDNA) is 1 of the most used and promising sources. Detecting tumor DNA among ccfDNA (ctDNA) can be used for early cancer detection, treatment response assessment, prognosis, and predictive evaluations. Providing analyses that can increase the quality of patient treatment is very much a joint effort between laboratory scientists and clinicians. With its use approaching clinical practice, it is important for clinicians to be familiar with the basic concepts and analyses behind ctDNA results in a similar way as laboratory scientists should have knowledge of the clinical needs to provide relevant analyses. In this Perspective, we describe the whole process of ctDNA analyses, from the preanalytical standards to reporting/analyzing results, and highlight some important factors that need to be addressed in the process of implementing them to clinical practice.

查看原文本刊更多论文

关于循环肿瘤DNA的实验室分析，临床医生需要知道什么？

液体活检提供了使用无创方法评估癌症患者的可能性。循环无细胞DNA （ccfDNA）是最常用和最有前途的来源之一。ccfDNA （ctDNA）中肿瘤DNA的检测可用于早期癌症检测、治疗反应评估、预后和预测评估。提供能够提高患者治疗质量的分析在很大程度上是实验室科学家和临床医生的共同努力。随着ctDNA的应用越来越接近临床实践，临床医生熟悉ctDNA结果背后的基本概念和分析是很重要的，就像实验室科学家应该了解临床需求以提供相关分析一样。在这个视角中，我们描述了ctDNA分析的整个过程，从分析前标准到报告/分析结果，并强调了在将其实施到临床实践过程中需要解决的一些重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.